Off-label use of infliximab

Onder M., Salavastru C., Fritz K.

HAUTARZT, cilt.64, sa.10, ss.757-761, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 64 Konu: 10
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00105-013-2596-z
  • Dergi Adı: HAUTARZT
  • Sayfa Sayıları: ss.757-761


Tumor necrosis factor alpha (TNF alpha) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNF alpha antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNF alpha activity. Numerous studies have shown TNF alpha antagonists to be effective in treating psoriasis-particularly severe resistant forms-and arthritis. Additionally, several case reports and studies showing the effects of TNF alpha on new dermatologic indications have been published. The intention of this review is to summarize the new off-label uses of infliximab according to published data.